



<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary) <b>PTO FORM 1449</b>	ATTY. DOCKET NO. <b>05882.0177.NPUS01</b>	APPLICATION NO. <b>10/741,657</b>
	APPLICANT <b>LAW, et al.</b>	
	FILING DATE <b>December 19, 2003</b>	GROUP <b>1631</b>

U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
SK	1.	6,183,968	09-29-81					
	2.	20020142951 A1	10-03-02					
	3.	20040005563 A1	01-08-04					
	4.							

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
SK	5.	EP 0 805 204	11-05-97	Europe				X
	6.	WO 98/45436	10-15-98	PCT				
	7.	WO 00/34473	06-15-00	PCT				
	8.	EP 1 033 401	09-06-00	Europe				
	9.	WO 00/56881	09-28-00	PCT				
	10.	WO 01/54477	08-12-01	PCT				
	11.	WO 01/70979	09-27-01	PCT				
	12.	WO 02/10449	02-07-02	PCT				
	13.	WO 02/61087	08-08-02	PCT				
	14.	WO 02/79406	10-10-02	PCT				
	15.	WO 02/83856	10-24-02	PCT				
	16.	WO 02/102235	12-27-02	PCT				
	17.	WO 03/038129	05-08-03	PCT				
	18.	WO 03/051925	06-26-03	PCT				
	19.	WO 03/071272	08-28-03	PCT				
	20.	WO 02/102235	12-27-02	PCT				

1 - 12/7/06

<b>LIST OF REFERENCES CITED BY APPLICANT</b> <i>(Use several sheets if necessary)</i>  <b>PTO FORM 1449</b>	ATTY. DOCKET NO. <b>05882.0177.NPUS01</b>	APPLICATION NO. <b>10/741,657</b>
	APPLICANT <b>LAW, et al.</b>	
	FILING DATE <b>December 19, 2003</b>	GROUP <b>1631</b>

<b>OTHER REFERENCES</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		
SK	21.	Osterhoff et al., "Cloning of a Human Epididymis-Specific mRNA, HE6, Encoding a Novel Member of the Seven Transmembrane-Domain Receptor Superfamily," DNA and Cell Biology, 16: 379-389 (1997)
	22.	Obermann et al., "HE6, a Two-Subunit Heptahelical Receptor Associated with Apical Membranes of Efficient Epididymal Duct Epithelia," Molec. Reprod. & Develop. 64: 13-26 (2003)
	23.	Gilewski et al., "Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21," Clin. Cancer Res. 6:1693-1701 (2000)
	24.	Scholl et al., "Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer," J. Immunother. 23:570-580 (2000)
	25.	Bon et al., "Clinical and technical evaluation of ACS BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays," Clin. Chem. 43:585-593 (1997)
	26.	Fitzgibbons et al., "Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999," Arch. Pathol. Lab. Med. 124:966-978 (2000)
	27.	Hamilton and Piccart, "The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2," Ann. Oncol. 11:647-663 (2000)
	28.	Robson, "Are BRCA1- and BRCA2-associated breast cancers different? Prognosis of BRCA1-associated breast cancer," J. Clin. Oncol. 18 (21 Suppl):113S-118S (2000)
	29.	GenBank accession X81892 (1996)
✓	30.	GenBank accession CAA57479 (1996)
	31.	

✓ 12/7/06

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary) <b>PTO FORM 1449</b>	ATTY. DOCKET NO.	APPLICATION NO.
	5882.0177.NPUS01	10/741,657
	APPLICANT	
	LAW, D. <i>et al.</i> ,	
	FILING DATE	GROUP
	December 29, 2003	1631

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1.						
	2.						
	3.						
	4.						
FOREIGN PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO.
	5.						
	6.						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
SR	7.	<del>International search report PCT/US03/40820</del>					
SR	8.	Fredriksson R., <i>et al.</i> , "Novel Human G Protein-Coupled Receptors with Long N-Terminal Containing GPS domains and Ser/Thr-Rich Regions" <i>FEBS Letters</i> <b>531</b> p 407-414, (2002)					
	9.						
	10.						
	11.						
	12.						
	13.						
	14.						
	15.						
	16.						

12/7/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.